[Portfolio Weekly Report 2026-06-25] Health Score: 6/10

[Portfolio Weekly Report 2026-06-25]

Health Score: 6/10 Total Floating P&L: Unknown (7 positions) Sector Distribution: Tech 61%, Healthcare 22%, Consumer Discretionary 11%, Financials 4%

⚠️ Concentration Risk: Tech sector at 61%, exceeding the single-sector cap of 50%

Key Risks:

• Tech concentration is as high as 61%, far above the 50% cap, leaving the portfolio overexposed to systemic risk
• EDIT, a gene-editing stock, is down 12.5% and underwater, highlighting the high-risk nature of biotech
• NFLX is up 63%, creating pullback risk; meanwhile, analyst consensus on INTC remains broadly bearish despite the stock's price resilience
• The portfolio includes 3 high-volatility mid/small-cap names (EDIT, ASTS, SOFI), so liquidity risk should not be ignored

Suggested Actions:

• Cut EDIT exposure to below 5% or exit and wait on the sidelines until gene-editing catalysts become clearer
• Bring tech allocation down to around 45%, with ASTS and other high-valuation names as likely trim candidates
• Consider scaling out of NFLX to lock in part of the gains against a potential pullback
• Add more defensive sectors (such as consumer staples or utilities) and target a 10-15% allocation to improve downside resilience

The portfolio is up about 37% ($10,980), so the overall profit picture is strong, but the risk structure has clear weaknesses. The biggest problem is tech at 61%, well above the single-sector cap, creating obvious concentration risk. At the stock level, EDIT is underwater (-12.5%) and remains a high-risk biotech name, NFLX has large open profits and meaningful drawdown risk, and INTC is materially diverging from analyst consensus, raising the chance of a catch-down move. The most urgent optimization is to rebalance sector exposure and reduce overconcentration in single names, mainly by trimming EDIT and selected tech positions, locking in some gains, and lowering overall portfolio volatility through broader diversification.